Top 5 Canadian Biotech Stocks in 2026
Biotech is a dynamic industry that is driving scientific advances and innovation in healthcare. In Canada, the biotech sector is home to companies pursuing cutting-edge therapies and medical technologies.
Here, the Investing News Network profiles the five best-performing Canadian biotech stocks on the TSX, TSXV and CSE, based on year-on-year gains. Data on these companies was collected on November 4, 2026, using TradingView’s stock screener, and companies with market caps above C$10 million at that time were considered.
Read on to learn what’s been driving these Canadian biotech firms.
1. BetterLife Pharma (CSE:BETR)
Year-on-year gain: 228.57 percent
Market cap: C$139.05 million
Share price: C$0.23
BetterLife Pharma describes itself as a biotech company developing treatments for brain and nervous system disorders.
Its lead candidate, BETR-001, is a modified version of LSD designed not to cause hallucinations. It’s being developed to prevent chronic cluster headaches and chronic migraines. In October, the company set up a scientific advisory board for this headache program as it prepares to apply to the US Food and Drug Administration (FDA) to begin human trials.
In September, BetterLife closed a US$100 million share sale, led by Deep Track Capital. The company plans to use the money for early safety trials in healthy volunteers, followed by trials in patients with cluster headache and migraine.
2. PharmAla Biotech (CSE:MDMA)
Year-on-year gain: 39.13 percent
Market cap: C$20.75 million
Share price: C$0.16
PharmAla Biotech has commercialized its clinical-grade LaNeo MDMA, the active ingredient in ecstasy, for clinical trials and for doctors licensed to prescribe it. PharmAla is also developing its own MDMA-based drug, ALA-002, and other novel MDXX compounds.
The company supplies the product within Canada and in several international jurisdictions. Through Cortexa, its Australian joint venture, the company supplies MDMA to psychiatrists in Australia, which has allowed MDMA for PTSD treatment since 2023.
Additionally, PharmAla signed a deal with Rua Bioscience to sell its MDMA in New Zealand in October. The prior month, the country approved some psychiatrists to prescribe it as part of a PTSD treatment program.
The company has also been making progress in the US. In April, PharmAla noted its established operations position is as a potential supplier of a new US program that a presidential executive order set up to give some patients access to experimental psychedelic drugs.
The company announced a licensing agreement with Jupiter Neurosciences (NASDAQ:JUNS) providing the latter company with a license to develop and commercialize ALA-002 in the US, while PharmAla retains the rights outside the US.
The following month, the company received a US patent covering its process for manufacturing the specific forms of MDMA it develops in a cost-effective manner.
3. Fennec…
Read More: Top 5 Canadian Biotech Stocks in 2026